ArticleiScience2026
Neutralization and ADCC reveal divergent spike-subdomain targeting across SARS-CoV-2 vaccine platforms in an African cohort.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evaluating demographically diverse antibody response dynamics remains relevant to developing better vaccines against SARS-CoV-2 and related coronaviruses. Here, in 80 Ugandan study participants vaccinated with BNT162b2, CoronaVac or ChAdOx1-S, we investigated longitudinal neutralization and antibody-dependent cellular cytotoxicity (ADCC) functions, correlating these with immunoglobulin G (IgG) binding dynamics to spike subdomains, receptor-binding domain, N-terminal domain, and S2, across variants. Neutralizing and ADCC responses differed by vaccine type and IgG subdomain binding profiles. S2-IgG binding and ADCC effector function dominated the immune response to CoronaVac vaccination, while BNT162b2 induced the most potent neutralizing antibodies. Overall, we reveal intra-population diversity in antibody binding, neutralization and ADCC among vaccinated individuals, many of whom exhibited elevated pre-vaccination S2-IgG, despite presumed absence of prior infection. There was confounding by vaccination scheduling amidst ongoing waves of infection. These data reveal distinct immunogenetic patterns in a sub-Saharan African population that could inform regionally tailored vaccine strategies and global pan-coronavirus vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.